Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease
Disease area: Airway diseases, Paediatric lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Ratjen, J. Salazar, R. Jensen, R. Amin, P. Gustafsson, S. Stanojevic, P. Subbarao (Toronto, Canada; Skoevde, Sweden). Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis. Eur Respir J 2012; 40: Suppl. 56, 1845

Member's Comments

No comment yet.

Related content which might interest you: Multiple breath washout in bronchiectasis clinical trials: is it feasible? Source: ERJ Open Res, 6 (4) 00363-2019; 10.1183/23120541.00363-2019 Year: 2020 The effect of spirometry on multiple breath washout outcomes in children with cystic fibrosis Source: International Congress 2018 – Cystic fibrosis in paediatric patients: current research Year: 2018 Change in functional lung MRI and multiple breath washout outcomes over one year in children with cystic fibrosis Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis Year: 2021 End-points and biomarkers for clinical trials in cystic fibrosis Source: Eur Respir Monogr 2014; 64: 104-115 Year: 2014 The concept of cystic fibrosis pulmonary exacerbation in clinical medicine and as a trial end-point Source: Annual Congress 2008 - Exacerbations of chronic respiratory disease – state of the art Year: 2008 The clinical utility of lung clearance index in early cystic fibrosis lung disease is not impacted by the number of multiple-breath washout trials Source: ERJ Open Res, 4 (1) 00094-2017; 10.1183/23120541.00094-2017 Year: 2018 Evaluation of SnIII parameters as outcome measures of multiple breath washout (MBW) in preschool children with cystic fibrosis Source: Virtual Congress 2021 – Monitoring of lung disease and CFTR function in children with cystic fibrosis Year: 2021 Nitrogen multiple breath washout test for infants with cystic fibrosis Source: Eur Respir J, 52 (2) 1800015; 10.1183/13993003.00015-2018 Year: 2018 Characterisation of leaks during multiple breath washout and their influence on test results Source: International Congress 2015 – Paediatric respiratory physiology Year: 2015 Differences in clinical features and biomarkers of subsequent acute cystic fibrosis pulmonary exacerbations - Analysing exacerbations as separate entities Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults Year: 2013 Doxycycline improves clinical outcomes during cystic fibrosis exacerbations Source: Eur Respir J , 49 (4)  1601102; DOI: 10.1183/13993003.01102-2016 Year: 2017 Intervention trials and ventilation distribution in mild cystic fibrosis lung disease: will it all come out in the wash? Source: Eur Respir J 2011; 37: 757-759 Year: 2011 Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice Source: International Congress 2015 – Treatment of IPF Year: 2015 Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation Source: International Congress 2018 – Cystic fibrosis in adults: current research Year: 2018 Nitrogen multiple breath washout indices as potentially prognostic markers in idiopathic pulmonary fibrosis Source: International Congress 2017 – Lung function testing Year: 2017 Do patients with cystic fibrosis participating in clinical trials demonstrate placebo response ? A meta-analysis. Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Heterogeneity of treatment response in bronchiectasis clinical trials Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria Year: 2020 Multiple breath washout: measuring early manifestations of lung pathology Source: Breathe, 17 (3) 210016; 10.1183/20734735.0016-2021 Year: 2021 Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences Source: Eur Respir Rev 2015; 24: 420-427 Year: 2015